News Releases | Insmed Incorporated

Month Year

Email Alerts

May 25, 2006

INSMED Announces IPLEX(TM) Availability Nationwide for Children with Severe Short Stature; IPLEX Launch Marked By The First Product Shipments To Patients in States Across the Country

Read more
May 12, 2006

Insmed Incorporated to Present at the Rodman & Renshaw 3rd Annual Healthcare Conference

Read more
May 8, 2006

Insmed Incorporated Reports Financial Results for the First Quarter Ended March 31, 2006

Read more
May 2, 2006

Insmed Inc. to Webcast 2006 First Quarter Financial Results Conference Call, Monday May 8, 2006 at 4:30 p.m. (ET)

Read more
May 1, 2006

IPLEX(TM) Demonstrates Significant, Dose-Dependent Increases in Growth Rate

Read more
Apr 26, 2006

Insmed Announces Podium Presentation at the Pediatric Academic Societies' 2006 Annual Meeting

Read more
Apr 25, 2006

NORD Honors Insmed for Role in Developing Treatments for Rare Diseases

Read more
Mar 22, 2006

Insmed Announces Additional Information in Compliance with NASDAQ Rules

Read more
Mar 15, 2006

Insmed Completes $46 Million Public Offering; Underwriters Exercise In Full Option to Purchase Additional Shares

Read more
Mar 10, 2006

Insmed Prices $40 Million Equity Offering

Read more
Mar 6, 2006

Insmed Incorporated Announces Proposed Public Offering of Common Stock

Read more
Mar 2, 2006

Insmed Incorporated Reports Financial Results for the Fourth Quarter and Twelve-Months of 2005

Read more
Feb 23, 2006

Insmed to Announce 2005 Fourth Quarter and Year End Financial Results; Thursday, March 2

Read more
Feb 3, 2006

Insmed Incorporated Files Shelf Registration Statement

Read more
Jan 4, 2006

U. of Rochester Initiates Phase 2 Clinical Trial of Insmed's iPlex for the Treatment of Myotonic Muscular Dystrophy; Trial Funded by NIH and MDA Grants

Read more
Dec 12, 2005

FDA Approves Insmed's Orphan Drug, IPLEX, for the Treatment of Severe Primary IGF-1 Deficiency; The First Once-Daily Therapy for the Treatment of Severe Primary IFG-1 Deficiency

Read more
Dec 8, 2005

Insmed Responds to Complaint Filed by Tercica

Read more
Nov 28, 2005

Insmed to Present at the Lazard Capital Markets Life Sciences Conference

Read more
Nov 5, 2005

Insmed Incorporated Reports Financial Results for the Third Quarter and First Nine Months of 2005

Read more
Nov 2, 2005

Insmed to Present at the Rodman and Renshaw 7th Annual Healthcare Conference

Read more
Nov 1, 2005

Insmed to Release Third Quarter Financial Results; Thursday, November 3

Read more
Oct 25, 2005

Insmed Receives European Orphan Drug Designation for SomatoKine for the Treatment of Extreme Insulin Resistance; Company to Initiate Clinial Trial in Type A Insulin Resistance

Read more
Oct 25, 2005

FDA to Review Insmed's Complete Response to Approvable Letter for iPlex

Read more
Oct 24, 2005

Insmed to Present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference

Read more
Oct 18, 2005

Insmed to Present at the BIO Investor Forum Conference

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation

Download

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Press Releases

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Footer